<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01291784</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 10-1450</org_study_id>
    <secondary_id>GC1008-JM</secondary_id>
    <nct_id>NCT01291784</nct_id>
  </id_info>
  <brief_title>Anti-TGF-beta Therapy in Patients With Myelofibrosis</brief_title>
  <official_title>Phase I Study of GC1008 in Patients With Primary Myelofibrosis (PMF), Post-polycythemia Vera/Essential Thrombocythemia Related Myelofibrosis (Post-PV/ET MF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John Mascarenhas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      TGF-β is a cytokine that is found to be upregulated in the bone marrow of patients with
      myelofibrosis. This cytokine likely plays a dual role in promoting myelofibrosis and
      myeloproliferation, both of which are the bone marrow morphologic hallmark of MF. The
      investigators propose that inhibiting the TGF-β signaling pathway in MF will decrease the
      fibrogenic stimuli leading to myelofibrosis and concomitantly interrupt myeloproliferation.
      This is a novel approach to the treatment of patients with myelofibrosis.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Early termination when the drug was no longer made available by the pharmaceutical company due
    to unanticipated management and administrative decisions.
  </why_stopped>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>28 days</time_frame>
    <description>To assess the safety and tolerability of GC1008 in patients with primary myelofibrosis (PMF) or post-polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET MF).
A total of 9 AEs determined by the investigator to be at least possibly related to GC1008 occurred during the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bauermeister Scale</measure>
    <time_frame>6 months</time_frame>
    <description>To assess the clinical response to therapy with GC1008 by International Working Group (IWG) criteria and measure the change in degree of bone marrow fibrosis (BMF) assessed by Bauermeister scale.
Bauermeister scale: 0, no demonstrable reticulin fibers; 1, occasional fine individual fibers and foci of a fine-fiber network; 2, fine fiber network throughout most of the section, but no coarse fibers; 3, diffuse fiber network with scattered thick coarse fibers, but no mature collagen; and 4, diffuse, often coarse fiber network with areas of collagen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Consensus Fibrosis Grade</measure>
    <time_frame>6 months</time_frame>
    <description>To assess the clinical response to therapy with GC1008 by International Working Group (IWG) criteria and measure the change in degree of bone marrow fibrosis (BMF) assessed by European consensus grading system.
This scheme consists of a qualitative (reticulin or collagen) and quantitative evaluation of bone marrow fibrosis and distinguishes four increasing categories, ranging from MF-0, which corresponds to normal bone marrow, to MF-3, in which coarse bundles of collagen fibrosis are identifiable with significant osteosclerosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral Blood CD34+</measure>
    <time_frame>6 months</time_frame>
    <description>Investigate exploratory markers for their ability to predict responsiveness to treatment with GC1008.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>JAK2V617F Allele Burden</measure>
    <time_frame>6 months</time_frame>
    <description>Investigate exploratory markers, hematopoietic cells, for their ability to predict responsiveness to treatment with GC1008. Analysis of percentage of mutant alleles in hematopoietic stem cells.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Myelofibrosis</condition>
  <condition>Primary Myelofibrosis</condition>
  <condition>Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase</condition>
  <condition>Post-essential Thrombocythemia Related Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>monoclonal antibody to TGF-beta</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>starting dose of 1mg/kg intravenous over approximately 1 hour every 4 weeks for a total of 6 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>monoclonal antibody to TGF-beta</intervention_name>
    <description>starting dose of 1mg/kg intravenous over approximately 1 hour every 4 weeks for a total of 6 doses</description>
    <arm_group_label>monoclonal antibody to TGF-beta</arm_group_label>
    <other_name>GC1008</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18

          -  ECOG 0-2

          -  Intermediate-1 or higher by IWG-MRT Post PV/ET MF patients OR intermediate-1 or higher
             JAK2V617F negative PMF

          -  Bone marrow MF-2 or higher as assessed by the European consensus grading score AND
             grade 3 or higher by modified Bauermeister scale.

          -  Patients must be able to give written informed consent to participate. Patients may
             not be consented by a durable power of attorney.

          -  Male and female patients of child-producing potential must agree to use effective
             contraception while enrolled on study and receiving the investigational agent, and for
             at least 3 months after the last treatment.

          -  At the time of enrollment, patients must be &gt;4 weeks since major surgery,
             radiotherapy, chemotherapy (except hydroxyurea) immunotherapy, or biotherapy/targeted
             therapies and recovered from the toxicity of prior treatment to &lt; Grade 1, exclusive
             of alopecia. Concurrent cancer therapy is not permitted for the exception of
             hydroxyurea if already being used at a stable dose for 3 weeks prior to screening.

          -  Patients must have negative tests for human immunodeficiency virus (HIV) and for
             hepatitis viruses B and C (antibody and/or antigen) unless the result is consistent
             with prior vaccination or prior infection with full recovery.

          -  Marrow: Absolute neutrophil count ≥ 500/mm3, and platelet count ≥50,000/mm3 without
             the need for platelet transfusion within 4 weeks

          -  Hepatic: Serum total bilirubin &gt;1.5 X upper limit of normal (ULN) (Patients with
             Gilbert's Disease may be included if their total bilirubin is &gt;3.0 mg/dL); alanine
             aminotransferase (ALT), and aspartate aminotransferase (AST) &gt;2.5 X ULN.

          -  Renal: Serum creatinine of &lt; 1.5 x upper limit of normal (ULN) or, if higher,
             estimated or measured creatinine clearance &gt;45 mL/min.

          -  Coagulation:

               1. Prothrombin Time (PT) &lt; 1.5 X ULN

               2. Partial thromboplastin time (aPTT) &lt; 1.5 X ULN

        Exclusion Criteria:

          -  Central nervous system (CNS) cancer or metastases, meningeal carcinomatosis, malignant
             seizures, or a disease that either causes or threatens neurologic compromise (e.g.,
             unstable vertebral metastases).

          -  Pregnant or nursing women, due to the unknown effects of GC1008 on the developing
             fetus or newborn infant.

          -  Patients with known bleeding diathesis or signs of uncontrolled active bleeding
             (hematuria, GI bleeding) other than self-limited causes of benign etiology that have
             been adequately investigated at the discretion of the investigator.

          -  Patients requiring anticoagulation with aspirin &gt; 81mg daily, unfractionated heparin,
             low molecular weight heparin (LMWH), direct anti-thrombin inhibitors, or vitamin K
             antagonists (e.g. warfarin). This does not apply to patients actively receiving
             aspirin at a dose of ≤ 81mg a day.

          -  Patients diagnosed with another malignancy - unless following curative intent therapy,
             the patient has been disease free for at least 5 years and the probability of
             recurrence of the prior malignancy is &gt;5%. Patients with curatively treated early
             stage squamous cell carcinoma of the skin, basal cell carcinoma of the skin, or
             cervical intraepithelial neoplasia (CIN) are eligible for this study.

          -  Patients with an organ transplant, including those that have received an allogeneic
             bone marrow transplant.

          -  Use of investigational agents within 4 weeks prior to study enrollment (within 6 weeks
             if the treatment was with a long-acting agent such as a monoclonal antibody).

          -  Significant or uncontrolled medical illness, such as congestive heart failure (CHF),
             myocardial infarction, symptomatic coronary artery disease, significant ventricular
             arrhythmias within the last 6 months, or significant pulmonary dysfunction. Patients
             with a remote history of asthma or active mild asthma may participate.

          -  Active autoimmune disorders or concurrent immunosuppressive medications such as
             prednisone, interferon, cyclosporine, methotrexate or azathioprine.

          -  Active infection requiring antibiotics.

          -  A known allergy to any component of GC1008.

          -  Patients who, in the opinion of the Investigator, have significant medical or
             psychosocial problems that warrant exclusion. Examples of significant problems
             include, but are not limited to:

               1. Other serious non-malignancy-associated medical conditions that may be expected
                  to limit life expectancy or significantly increase the risk of SAEs.

               2. Any condition, psychiatric, substance abuse, or otherwise, that, in the opinion
                  of the Investigator, would preclude informed consent, consistent follow-up, or
                  compliance with any aspect of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Mascarenhas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronald Hoffman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Mascarenhas J, Li T, Sandy L, Newsom C, Petersen B, Godbold J, Hoffman R. Anti-transforming growth factor-β therapy in patients with myelofibrosis. Leuk Lymphoma. 2014 Feb;55(2):450-2. doi: 10.3109/10428194.2013.805329. Epub 2013 Jun 24.</citation>
    <PMID>23682558</PMID>
  </results_reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2011</study_first_submitted>
  <study_first_submitted_qc>February 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2011</study_first_posted>
  <results_first_submitted>July 31, 2013</results_first_submitted>
  <results_first_submitted_qc>August 13, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 28, 2014</results_first_posted>
  <last_update_submitted>November 21, 2014</last_update_submitted>
  <last_update_submitted_qc>November 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>John Mascarenhas</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>monoclonal antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period from Jan 2011 to Feb 2012 of known patients to the medical clinic.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sub A</title>
          <description>Subject A</description>
        </group>
        <group group_id="P2">
          <title>Sub B</title>
          <description>Subject B</description>
        </group>
        <group group_id="P3">
          <title>Sub C</title>
          <description>Subject C</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>patients with intermediate -1 or higher primary myelofibrosis (PMF) or post-polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET MF). Patients were eligible if they had documented BMF of MF-2 or higher as assessed by the European consensus grading score and grade 3 or higher by modified Bauermeister scale.</population>
      <group_list>
        <group group_id="B1">
          <title>Phase 1 MF Subjects</title>
          <description>3 subjects were enrolled in the study. The three subjects were treated at a GC1008 dose level of 1 mg/kg given intravenously over approximately 60 minutes and then repeated every 28 days for a total of 6 cycles in the core study period and then an additional 6 cycles in an extension phase.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Actual age</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.67" spread="10.07" lower_limit="70" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability</title>
        <description>To assess the safety and tolerability of GC1008 in patients with primary myelofibrosis (PMF) or post-polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET MF).
A total of 9 AEs determined by the investigator to be at least possibly related to GC1008 occurred during the study.</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sub A</title>
            <description>Subject A</description>
          </group>
          <group group_id="O2">
            <title>Sub B</title>
            <description>Subject B</description>
          </group>
          <group group_id="O3">
            <title>Sub C</title>
            <description>Subject C</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability</title>
          <description>To assess the safety and tolerability of GC1008 in patients with primary myelofibrosis (PMF) or post-polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET MF).
A total of 9 AEs determined by the investigator to be at least possibly related to GC1008 occurred during the study.</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bauermeister Scale</title>
        <description>To assess the clinical response to therapy with GC1008 by International Working Group (IWG) criteria and measure the change in degree of bone marrow fibrosis (BMF) assessed by Bauermeister scale.
Bauermeister scale: 0, no demonstrable reticulin fibers; 1, occasional fine individual fibers and foci of a fine-fiber network; 2, fine fiber network throughout most of the section, but no coarse fibers; 3, diffuse fiber network with scattered thick coarse fibers, but no mature collagen; and 4, diffuse, often coarse fiber network with areas of collagen.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sub A</title>
            <description>Subject A</description>
          </group>
          <group group_id="O2">
            <title>Sub B</title>
            <description>Subject B</description>
          </group>
          <group group_id="O3">
            <title>Sub C</title>
            <description>Subject C</description>
          </group>
        </group_list>
        <measure>
          <title>Bauermeister Scale</title>
          <description>To assess the clinical response to therapy with GC1008 by International Working Group (IWG) criteria and measure the change in degree of bone marrow fibrosis (BMF) assessed by Bauermeister scale.
Bauermeister scale: 0, no demonstrable reticulin fibers; 1, occasional fine individual fibers and foci of a fine-fiber network; 2, fine fiber network throughout most of the section, but no coarse fibers; 3, diffuse fiber network with scattered thick coarse fibers, but no mature collagen; and 4, diffuse, often coarse fiber network with areas of collagen.</description>
          <units>units on a scale</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>European Consensus Fibrosis Grade</title>
        <description>To assess the clinical response to therapy with GC1008 by International Working Group (IWG) criteria and measure the change in degree of bone marrow fibrosis (BMF) assessed by European consensus grading system.
This scheme consists of a qualitative (reticulin or collagen) and quantitative evaluation of bone marrow fibrosis and distinguishes four increasing categories, ranging from MF-0, which corresponds to normal bone marrow, to MF-3, in which coarse bundles of collagen fibrosis are identifiable with significant osteosclerosis.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sub A</title>
            <description>Subject A</description>
          </group>
          <group group_id="O2">
            <title>Sub B</title>
            <description>Subject B</description>
          </group>
          <group group_id="O3">
            <title>Sub C</title>
            <description>Subject C</description>
          </group>
        </group_list>
        <measure>
          <title>European Consensus Fibrosis Grade</title>
          <description>To assess the clinical response to therapy with GC1008 by International Working Group (IWG) criteria and measure the change in degree of bone marrow fibrosis (BMF) assessed by European consensus grading system.
This scheme consists of a qualitative (reticulin or collagen) and quantitative evaluation of bone marrow fibrosis and distinguishes four increasing categories, ranging from MF-0, which corresponds to normal bone marrow, to MF-3, in which coarse bundles of collagen fibrosis are identifiable with significant osteosclerosis.</description>
          <units>units on a scale</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peripheral Blood CD34+</title>
        <description>Investigate exploratory markers for their ability to predict responsiveness to treatment with GC1008.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sub A</title>
            <description>Subject A</description>
          </group>
          <group group_id="O2">
            <title>Sub B</title>
            <description>Subject B</description>
          </group>
          <group group_id="O3">
            <title>Sub C</title>
            <description>Subject C</description>
          </group>
        </group_list>
        <measure>
          <title>Peripheral Blood CD34+</title>
          <description>Investigate exploratory markers for their ability to predict responsiveness to treatment with GC1008.</description>
          <units>percentage of hematopoietic stem cells</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>JAK2V617F Allele Burden</title>
        <description>Investigate exploratory markers, hematopoietic cells, for their ability to predict responsiveness to treatment with GC1008. Analysis of percentage of mutant alleles in hematopoietic stem cells.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sub A</title>
            <description>Subject A</description>
          </group>
          <group group_id="O2">
            <title>Sub B</title>
            <description>Subject B</description>
          </group>
          <group group_id="O3">
            <title>Sub C</title>
            <description>Subject C</description>
          </group>
        </group_list>
        <measure>
          <title>JAK2V617F Allele Burden</title>
          <description>Investigate exploratory markers, hematopoietic cells, for their ability to predict responsiveness to treatment with GC1008. Analysis of percentage of mutant alleles in hematopoietic stem cells.</description>
          <units>percentage of mutant alleles</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="95"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sub A</title>
          <description>Subject A</description>
        </group>
        <group group_id="E2">
          <title>Sub B</title>
          <description>Subject B</description>
        </group>
        <group group_id="E3">
          <title>Sub C</title>
          <description>Subject C</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Asystole</sub_title>
                <description>This event was deemed to not be drug related. Participant progressed to MF</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>leukocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>leukopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin lesions</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination when the drug was no longer made available by the pharmaceutical company due to unanticipated management and administrative decisions.
Limited patient data (2 evaluable patients), a dose accumulation ratio cannot be determined.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. John O. Mascarenhas</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>212-241-6756</phone>
      <email>john.mascarenhas@mssm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

